Radiopharm Theranostics (RDPTF) Minority Interest (2024 - 2026)

Radiopharm Theranostics (RDPTF) has reported Minority Interest for 3 consecutive years, with -$16765.8 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Minority Interest fell 36.34% year-over-year to -$16765.8 in Q2 2026; TTM through Jun 2026 was -$16765.8, a 36.34% decrease from a year earlier, with the FY2026 full-year figure at -$16052.1, up 99.16% from the prior year.
• Minority Interest was -$16765.8 for Q2 2026 at Radiopharm Theranostics, down from -$12297.0 in the prior quarter.
• Over five years, Minority Interest peaked at -$5069.7 in Q2 2024 and troughed at -$1.2 million in Q4 2024.
• A 3-year average of -$308105.6 and a median of -$14531.4 in 2025 frame the typical range for Minority Interest.
• Across the five-year window, Minority Interest plunged 142.56% in 2025 and tumbled 36.34% in 2026, its largest moves.
• Over 3 years, Minority Interest stood at -$1.2 million in 2024, then soared by 98.97% to -$12297.0 in 2025, then tumbled by 36.34% to -$16765.8 in 2026.
• The last three Minority Interest figures came in at -$16765.8 (Q2 2026), -$12297.0 (Q2 2025), and -$1.2 million (Q4 2024), per Business Quant data.